Loading
companiesCompany
Sobi (Swedish Orphan Biovitrum)
Sobi is a Swedish rare-disease company whose haematology and oncology supportive products include palifermin (Kepivance) for severe oral mucositis, avatrombopag (Doptelet) and emapalumab (Gamifant).
Also called: CTI BioPharma
Overview
Swedish Orphan Biovitrum markets Kepivance (palifermin) for mucositis after high-dose chemotherapy with stem cell support, Doptelet (avatrombopag) for thrombocytopenia, Gamifant (emapalumab) for haemophagocytic lymphohistiocytosis and Zynlonta (loncastuximab tesirine) in Europe under licence from ADC Therapeutics.
Headquarters
Stockholm, SE
Scorecard
All companies#118of 1244 companies, score 46
- approved products +12
- targets +6
- modalities +6
- regions +2
- registry trials +20
2 approved, 0 in phase 3, 0 earlier, 3 targets, 97 registry studies. Formula on the scorecards page.
Type
Large pharma · SOBI.ST
Stage
Public
Website
ApprovedRecombinant human keratinocyte growth factor
Palifermin · Kepivance
Palifermin (Kepivance) is a growth factor injected for three days before and after high-dose chemotherapy and stem cell rescue to reduce the severe mouth ulcers (mucositis) that this treatment causes in people with blood cancers.
EstablishedAnti-interferon-gamma monoclonal antibody
Emapalumab · Gamifant
Emapalumab switches off interferon gamma, the signal behind the runaway immune activation of haemophagocytic lymphohistiocytosis (HLH), a condition that can also be triggered by lymphoma and by CAR-T therapy.
ApprovedSmall-molecule JAK2/IRAK1/ACVR1 inhibitor
Pacritinib · Vonjo
The JAK inhibitor for myelofibrosis patients whose platelet counts are too low for ruxolitinib.
drugs
EstablishedAnti-interferon-gamma monoclonal antibody
Emapalumab · Gamifant
ApprovedSmall-molecule JAK2/IRAK1/ACVR1 inhibitor
Pacritinib · Vonjo
ApprovedRecombinant human keratinocyte growth factor
Palifermin · Kepivance
companies
terms
trials
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple MyelomaPacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic LeukemiaPalifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck CancerPalifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)